pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL MYERS SQUIBB CO ($BMY) · news · pharmadog
← back to BRISTOL MYERS SQUIBB CO
News mentioning $BMY
346
stories
9d
Bayer wins FDA nod for a new kind of blood thinner
biopharma dive
10d
With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys
biospace
12d
Forge’s Piteri-Molina on AI, Ohio and what’s next for gene therapy manufacturing
biospace
13d
Merck abandons Sutro-partnered IL-2 drug in ‘routine pipeline prioritization’
fiercebiotech
14d
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
biospace
14d
AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
fiercebiotech
15d
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance
biospace
16d
BioArctic left out in the cold as Novartis walks away from $800M neuro collab
fiercebiotech
16d
Tiziana touts multiple sclerosis win at lower dose as high dose misses mark
biospace
16d
Cell therapy investment grows as safety events rankle Big Pharma's CAR T autoimmune push
biospace
17d
China's InventisBio delivers competitive TYK2 data in phase 3 psoriasis win
fiercebiotech
19d
Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed back
endpoints
20d
Bristol Myers defends pipeline, reinforces later-stage BD interest
endpoints
20d
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
biospace
20d
BMS walks away from $80M neurodegeneration bet after phase 1
fiercebiotech
21d
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
biospace
22d
Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes
fiercebiotech
22d
Big Pharma is ready to strike, with J&J most likely to buy: Leerink
biospace
22d
5 new drug launches that defied industry expectations
biospace
22d
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
biopharma dive
22d
Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy
fiercebiotech
22d
From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama
fiercebiotech
23d
STAT+: Roche gets a lung cancer win with its KRAS drug divarasib
stat
23d
ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
biopharma dive
23d
ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
biospace
23d
Another autoimmune CAR-T death; Treasury zeroes in on China deals
biopharma dive
23d
STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
stat
23d
STAT+: Five biotech updates to read after ESMO this weekend
stat
23d
STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more
stat
23d
BMS joins 3-year partnership to boost participation in cancer trials
fiercebiotech
← prev
page 2 of 12
next →